Bausch & Lomb's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 85.35.
Bausch & Lomb's Days Inventory for the
three
months ended in Mar. 2026 was 184.48.
Bausch & Lomb's Days Payable for the
three
months ended in Mar. 2026 was 75.1.
Therefore, Bausch & Lomb's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 194.73.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Bausch & Lomb Cash Conversion Cycle Related Terms
Bausch & Lomb Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Bausch & Lomb's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLCO vs ISRG, BDX, MDLN: Cash Conversion Cycle Comparison
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Bausch & Lomb's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a Cash Conversion Cycle of 194.73 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Bausch & Lomb and its competitors.
Is Bausch & Lomb's Cash Conversion Cycle too high?
Bausch & Lomb's current Cash Conversion Cycle is 194.73. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.39. Bausch & Lomb's value of 194.73 is 24.5% above this industry median. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's Cash Conversion Cycle compare to ISRG and BDX?
Bausch & Lomb's Cash Conversion Cycle of 194.73 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.39. Bausch & Lomb's value of 194.73 is 24.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.39, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current Cash Conversion Cycle of 194.73 is 24.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current Cash Conversion Cycle is 194.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Fairly Valued. The stock's GF Value™ is $18.37, compared to a current price of $16.63 — trading 9.5% below its estimated fair value. The current Cash Conversion Cycle is 194.73 and 24.5% above the Medical Devices & Instruments industry median of 156.39. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current Cash Conversion Cycle is 194.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $16.63 is trading 9.5% below its estimated GF Value™ of $18.37.
GuruFocus considers Bausch & Lomb to be Fairly Valued.
Key valuation signals for BLCO:
Cash Conversion Cycle: 194.73
GF Value™: $18.37 vs. price of $16.63 (9.5% below fair value)
Industry Position: 24.5% above the Medical Devices & Instruments median
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
